Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Codexis (CDXS) Stock Price

Media coverage about Codexis (NASDAQ:CDXS) has trended somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Codexis earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.6041023264337 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern’s scoring:

A number of analysts have recently issued reports on the company. HC Wainwright set a $8.00 target price on Codexis and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research lowered Codexis from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research report on Sunday, July 16th. Jefferies Group LLC lifted their target price on Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, October 13th. Finally, ValuEngine raised Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Codexis currently has an average rating of “Hold” and an average target price of $7.50.

Shares of Codexis (NASDAQ:CDXS) traded down $0.10 during trading on Monday, reaching $6.25. The company had a trading volume of 205,700 shares, compared to its average volume of 167,966. Codexis has a 1 year low of $3.60 and a 1 year high of $7.95.

In related news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $5.78, for a total value of $6,126,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.80% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Codexis (CDXS) Stock Price” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-codexis-cdxs-stock-price.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply